Pregnancy and survival-related outcomes of uveal melanoma treated with brachytherapy in women of reproductive age.
Humans
Female
Brachytherapy
/ methods
Uveal Neoplasms
/ radiotherapy
Pregnancy
Melanoma
/ radiotherapy
Retrospective Studies
Adult
Pregnancy Outcome
Follow-Up Studies
Iodine Radioisotopes
/ therapeutic use
Young Adult
Pregnancy Complications, Neoplastic
/ radiotherapy
Survival Rate
/ trends
Prognosis
Middle Aged
Plaque brachytherapy
Pregnancy
Uveal melanoma
Journal
BMC ophthalmology
ISSN: 1471-2415
Titre abrégé: BMC Ophthalmol
Pays: England
ID NLM: 100967802
Informations de publication
Date de publication:
27 Sep 2024
27 Sep 2024
Historique:
received:
22
06
2023
accepted:
14
09
2024
medline:
28
9
2024
pubmed:
28
9
2024
entrez:
28
9
2024
Statut:
epublish
Résumé
To examine if pregnancy affects the prognosis of uveal melanoma (UM) patients undergoing plaque brachytherapy (PBT) and to assess if PBT has any subsequent impact on pregnancy outcomes. A retrospective, single-center study was carried out at Beijing Tongren Hospital, focusing on women of childbearing age diagnosed with UM and treated with iodine-125 plaque brachytherapy. Both the outcomes of pregnancies and the health status of the fetuses were monitored. Survival analyses were conducted using the Kaplan-Meier method, with endpoints being metastasis and death. A total of 13 patients who had full-term pregnancies and 96 non-pregnant women matched by age and tumor size were included. The mean follow-up time was 67.0 ± 27.7 months (median:66.0 months, range:21.0 to 116.0 months). In the pregnant group, two patients developed metastases, one of whom died shortly after delivery; local recurrence of UM occurred in 2 patients after or during delivery, and 2 other patients developed secondary glaucoma due to radiation retinopathy. None of the other pregnant patients reported any signs of disease progression. In the control group, 18 metastasis cases including 12 deaths were documented. Pregnant patients and matched control subjects showed no statistical difference in both Metastasis-free survival (hazard ratio (HR): 0.66, 95% confidence interval (CI): 0.15-2.86; P = 0.576) and overall survival (HR: 0.48, 95% CI: 0.06-3.66; P = 0.464). All pregnant patients carried the pregnancy to term and delivered healthy children with no report of placental or infant metastases to date. Pregnancy does not appear to negatively impact the prognosis of UM patients undergoing PBT. PBT showed no observable detriment to maternal fertility and exhibited no teratogenic effects on the fetus. However, the long-term implications of PBT on pregnancy remain uncertain, necessitating additional, prolonged follow-up studies.
Sections du résumé
BACKGROUND
BACKGROUND
To examine if pregnancy affects the prognosis of uveal melanoma (UM) patients undergoing plaque brachytherapy (PBT) and to assess if PBT has any subsequent impact on pregnancy outcomes.
METHODS
METHODS
A retrospective, single-center study was carried out at Beijing Tongren Hospital, focusing on women of childbearing age diagnosed with UM and treated with iodine-125 plaque brachytherapy. Both the outcomes of pregnancies and the health status of the fetuses were monitored. Survival analyses were conducted using the Kaplan-Meier method, with endpoints being metastasis and death.
RESULTS
RESULTS
A total of 13 patients who had full-term pregnancies and 96 non-pregnant women matched by age and tumor size were included. The mean follow-up time was 67.0 ± 27.7 months (median:66.0 months, range:21.0 to 116.0 months). In the pregnant group, two patients developed metastases, one of whom died shortly after delivery; local recurrence of UM occurred in 2 patients after or during delivery, and 2 other patients developed secondary glaucoma due to radiation retinopathy. None of the other pregnant patients reported any signs of disease progression. In the control group, 18 metastasis cases including 12 deaths were documented. Pregnant patients and matched control subjects showed no statistical difference in both Metastasis-free survival (hazard ratio (HR): 0.66, 95% confidence interval (CI): 0.15-2.86; P = 0.576) and overall survival (HR: 0.48, 95% CI: 0.06-3.66; P = 0.464). All pregnant patients carried the pregnancy to term and delivered healthy children with no report of placental or infant metastases to date.
CONCLUSION
CONCLUSIONS
Pregnancy does not appear to negatively impact the prognosis of UM patients undergoing PBT. PBT showed no observable detriment to maternal fertility and exhibited no teratogenic effects on the fetus. However, the long-term implications of PBT on pregnancy remain uncertain, necessitating additional, prolonged follow-up studies.
Identifiants
pubmed: 39333941
doi: 10.1186/s12886-024-03681-6
pii: 10.1186/s12886-024-03681-6
doi:
Substances chimiques
Iodine Radioisotopes
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
416Subventions
Organisme : National Natural Science Foundation of China
ID : 82141128
Organisme : The Capital Health Research and Development of Special
ID : 2020-1-2052
Organisme : Science & Technology Project of Beijing Municipal Science & Technology Commission
ID : Z201100005520045
Informations de copyright
© 2024. The Author(s).
Références
Jager MJ, Shields CL, Cebulla CM, Abdel-Rahman MH, Grossniklaus HE, Stern MH, et al. Uveal melanoma. Nat Rev Dis Primers. 2020;6(1):24.
doi: 10.1038/s41572-020-0158-0
pubmed: 32273508
Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011;118(9):1881–5.
doi: 10.1016/j.ophtha.2011.01.040
pubmed: 21704381
Shields CL, Shields JA, Cater J, z, KGn, Miyamoto C, Micaily B et al. Plaque Radiotherapy for Uveal Melanoma: Long-term Visual Outcome in 1106 Consecutive Patients. Arch Ophthalmol. 2000(118):1219-28.
Diener-West M, Earle JD, Fine SL. The COMS Randomized Trial of Iodine 125 Brachytherapy for Choroidal Melanoma, III: initial mortality findings. AMA Archives Ophthalmol. 2001(119):969–82.
Jampol LM, Moy CS, Murray TG, Reynolds SM, Albert DM, Schachat AP, et al. The COMS Randomized Trial of Iodine 125 Brachytherapy for Choroidal Melanoma: IV. Local Treatment Failure and enucleation in the first 5 years after Brachytherapy. COMS Rep 19 Ophthalmol. 2020;127(4S):S148–57.
Singh N, Bergman L, Seregard S, Singh AD. Uveal melanoma: epidemiologic aspect. Berlin Heidelberg: Springer; 2014.
Kaliki S, Shields CL. Uveal melanoma: relatively rare but deadly cancer. Eye (Lond). 2017;31(2):241–57.
doi: 10.1038/eye.2016.275
pubmed: 27911450
Hartman M, Liu J, Czene K, Miao H, Chia KS, Salim A, et al. Birth rates among female cancer survivors: a population-based cohort study in Sweden. Cancer. 2013;119(10):1892–9.
doi: 10.1002/cncr.27929
pubmed: 23436251
Naderan M. Ocular changes during pregnancy. J Curr Ophthalmol. 2018;30(3):202–10.
doi: 10.1016/j.joco.2017.11.012
pubmed: 30197948
pmcid: 6127369
Hartge P, Tucker MA, Shields JA, Augsburger J, Hoover RN, Joseph F, Fraumeni J. Case-Control Study of Female hormones and Eye Melanoma. cancer Resaearch. 1989(49):4622–5.
Zinkhan M, Stang A, Jockel KH, Marr A, Bornfeld N, Schmidt-Pokrzywniak A. Having children, social characteristics, smoking and the risk of uveal melanoma: a case-control study. Ophthalmic Epidemiol. 2013;20(6):360–8.
doi: 10.3109/09286586.2013.844842
pubmed: 24229069
Holly EA, Aston DA, Ahn DK, Kristiansen JJ, Char DH. Uveal Melanoma, Hormonal and Reproductive factors in women. cancer Resaearch. 1991(51):1370–2.
Egan KM, Walsh SM, Seddon JM, Gragoudas ES. An evaluation of the influence of Reproductive factors on the risk of metastases from Uveal Melanoma. Ophthalmology. 1993(100):1160–6.
Lemaitre S, Levy-Gabriel C, Desjardins L, Plancher C, Asselain B, Vincent-Salomon A, et al. Choroidal melanoma and pregnancy. Acta Ophthalmol. 2016;94(7):e652–60.
doi: 10.1111/aos.12984
pubmed: 27009598
Egan KM, Quinn JL, Gragoudas ES. Childbearing history Associated with Improved Survival in Choroidal Melanoma. Arch Ophthalmol. 1999(117):939–42.
Seddon JM, Maclaughlin DT, Albert DM, Gragoudas ES, MF III. Uveal melanoma presenting during pregnancy and the investigation of oestrogen receptors in melanomas. Br J Ophthalmol. 1982;66:695–704.
Lee CS, Yang WI, Shin KJ, Lee SC. Rapid growth of choroidal melanoma during pregnancy. Acta Ophthalmol. 2011;89(3):e290–1.
doi: 10.1111/j.1755-3768.2009.01803.x
pubmed: 19958288
Yue H, Qian J, Ren H, Zhang R, Gan L, Bi YW. Accelerated growth of uveal melanoma related to pregnancy: a case report and literature review. Int J Ophthalmol. 2021;14(2):326–9.
doi: 10.18240/ijo.2021.02.23
pubmed: 33614466
pmcid: 7840378
Shields CL, Shields JA, Karlsson U, Menduke H, Brady LW. Enucleation after Plague Radiotherapy for Posterior Uveal Melanoma. Ophthalmology. 1990;97(12):1665–70.
doi: 10.1016/S0161-6420(90)32363-1
pubmed: 2087297
Shields CL, Shields JA Jr., Potter RCE, Menduke PD. Uveal melanoma and pregnancy: a report of 16 cases. Ophthalmology. 1991;98(98):1667–73.
doi: 10.1016/S0161-6420(91)32060-8
pubmed: 1800927
Miller E, Barnea Y, Gur E, Leshem D, Karin E, Weiss J, et al. Malignant melanoma and pregnancy: second thoughts. J Plast Reconstr Aesthet Surg. 2010;63(7):1163–8.
doi: 10.1016/j.bjps.2009.05.050
pubmed: 19592319
Schmidt-Pokrzywniak A, Kalbitz S, Kuss O, Jöckel K-H, Bornfeld N, Stang A. Assessment of the effect of iris colour and having children on 5-year risk of death after diagnosis of uveal melanoma: a follow-up study. BMC Ophthalmol. 2014;14:42.
doi: 10.1186/1471-2415-14-42
pubmed: 24685257
pmcid: 3998741
Marsh RW, Chu N-M. Placental metastasis from primary ocular melanoma: a case report. Am J Obstet Gynecol. 1996(174):1654–5.
Park SJ, Oh CM, Kim BW, Woo SJ, Cho H, Park KH. Nationwide Incidence of Ocular Melanoma in South Korea by using the National Cancer Registry Database (1999–2011). Invest Ophthalmol Vis Sci. 2015;56(8):4719–24.
doi: 10.1167/iovs.15-16532
pubmed: 26207308